These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 25852058)

  • 1. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.
    Eilers G; Czaplinski JT; Mayeda M; Bahri N; Tao D; Zhu M; Hornick JL; Lindeman NI; Sicinska E; Wagner AJ; Fletcher JA; Mariño-Enriquez A
    Mol Cancer Ther; 2015 Jun; 14(6):1346-53. PubMed ID: 25852058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coamplification of 12q15 and 12p13 and homozygous CDKN2A/2B deletion: synergistic role of fibrosarcomatous transformation in dermatofibrosarcoma protuberans with a cryptic COL1A1-PDGFB fusion.
    Lu Y; Li T; Chen M; Peng H; Du T; Qiu Y; Zhang H
    Virchows Arch; 2022 Aug; 481(2):313-319. PubMed ID: 35171326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications.
    Ha SY; Lee SE; Kwon MJ; Kim YJ; Lee EH; Seo J; Jang KT; Lee J; Choi YL
    Hum Pathol; 2013 Jul; 44(7):1300-9. PubMed ID: 23347652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
    Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
    Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
    Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
    Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing.
    Hong JY; Liu X; Mao M; Li M; Choi DI; Kang SW; Lee J; La Choi Y
    PLoS One; 2013; 8(7):e69752. PubMed ID: 23922791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.
    Kambayashi Y; Kasahara Y; Ohuchi K; Amagai R; Hashimoto A; Asano Y; Fujimura T
    Dermatol Ther; 2022 Oct; 35(10):e15736. PubMed ID: 35898161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss.
    Stacchiotti S; Astolfi A; Gronchi A; Fontana A; Pantaleo MA; Negri T; Brenca M; Tazzari M; Urbini M; Indio V; Colombo C; Radaelli S; Brich S; Dei Tos AP; Casali PG; Castelli C; Dagrada GP; Pilotti S; Maestro R
    Mol Cancer Res; 2016 Sep; 14(9):820-9. PubMed ID: 27256159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans.
    Oh E; Jeong HM; Kwon MJ; Ha SY; Park HK; Song JY; Kim YJ; Choi JS; Lee EH; Lee J; Choi YL; Shin YK
    PLoS One; 2017; 12(10):e0185826. PubMed ID: 28977029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
    McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Ugurel S; Mentzel T; Utikal J; Helmbold P; Mohr P; Pföhler C; Schiller M; Hauschild A; Hein R; Kämpgen E; Kellner I; Leverkus M; Becker JC; Ströbel P; Schadendorf D
    Clin Cancer Res; 2014 Jan; 20(2):499-510. PubMed ID: 24173542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of gene mutations in three cases of dermatofibrosarcoma protuberans (DFSP): ordinary DFSP, DFSP with fibrosarcomatous lesion (DFSP-FS) and lung metastasis of DFSP-FS.
    Saeki H; Hoashi T; Tada Y; Ashida R; Kuwano Y; Le Pavoux A; Tsunemi Y; Shikada J; Torii H; Kawabata Y; Kikuchi K; Tamada Y; Matsumoto Y; Tamaki K
    J Dermatol Sci; 2003 Dec; 33(3):161-7. PubMed ID: 14643521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
    Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
    Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and characterization of NCC-DFSP5-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line.
    Ono T; Noguchi R; Osaki J; Akiyama T; Adachi Y; Kojima N; Toda Y; Fukushima S; Yoshimatsu Y; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2024 May; 37(3):854-864. PubMed ID: 38372888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
    Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
    Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
    Hisaoka M; Okamoto S; Morimitsu Y; Tsuji S; Hashimoto H
    Virchows Arch; 1998 Oct; 433(4):323-9. PubMed ID: 9808434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants.
    Jahanseir K; Xing D; Greipp PT; Sukov WR; Keeney GL; Howitt BE; Schoolmeester JK
    Int J Gynecol Pathol; 2018 Nov; 37(6):537-546. PubMed ID: 29140881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of PDGFRβ-Akt-mTOR pathway signaling in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
    Hiraki-Hotokebuchi Y; Yamada Y; Kohashi K; Yamamoto H; Endo M; Setsu N; Yuki K; Ito T; Iwamoto Y; Furue M; Oda Y
    Hum Pathol; 2017 Sep; 67():60-68. PubMed ID: 28711648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).
    Stacchiotti S; Pantaleo MA; Negri T; Astolfi A; Tazzari M; Dagrada GP; Urbini M; Indio V; Maestro R; Gronchi A; Fiore M; Dei Tos AP; Conca E; Palassini E; Vincenzi B; Grosso F; Pilotti S; Castelli C; Casali PG
    Clin Cancer Res; 2016 Feb; 22(4):837-46. PubMed ID: 26261104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.